TEANECK, N.J., June 28, 2016 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that Biogen (NASDAQ: BIIB) has selected Cognizant's SmartTrials™ platform to aggregate and store clinical trial operational and patient data. Cambridge, Mass.-based Biogen has the leading portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of neurology research, working to develop novel therapies for conditions with few or no treatment options.
The SmartTrials platform provides real-time risk assessment and global clinical trial oversight to help companies reduce risk and improve collaboration, quality and compliance. It delivers actionable outcomes for faster data-driven decisions, transforming clinical operations into a more agile, innovative and efficient process. The SmartTrials platform allows biopharma companies to support clinical operations by standardizing data exchange, and replacing several data repositories with a centralized information hub.
"We are excited to partner with leading biopharma companies to drive innovation in clinical development," said Bhaskar Sambasivan, Vice President of Life Sciences practice at Cognizant. "The SmartTrials platform makes it easier for users and decision makers to more effectively monitor clinical trial progress, reduce risk and costs, with the goal of bringing new therapies to market faster."
Learn more about Cognizant SmartTrials:
About Cognizant's Healthcare and Life Sciences Practice
Cognizant's Healthcare and Life Sciences practice, which includes the TriZetto software portfolio, is committed to helping change millions of lives for the better by partnering with clients to build solutions to healthcare challenges, continually improve the way they do business, set the pace in clinical development, strengthen their regulatory infrastructure, and increase competitiveness. With approximately $3.5 billion in annualized revenue, Cognizant's healthcare practice is ranked number three on the Healthcare Informatics Top 100. Cognizant serves 28 of the top 30 global pharmaceutical companies, 16 of the top 20 health plans in the U.S., 3 of the top 5 pharmacy benefit management companies in the U.S., 9 of the top 10 biotech companies, and 12 of the top 15 medical device companies. With a large team of dedicated professionals including doctors, pharmacologists, physicians, biomedical engineers, pharmacists, biostatisticians, medical writers, and GxP consultants, the practice provides domain-aligned consulting, IT, business process, software and as-a-service solutions globally.
Cognizant (NASDAQ: CTSH) is a leading provider of information technology, consulting, and business process services, dedicated to helping the world's leading companies build stronger businesses. Headquartered in Teaneck, New Jersey (U.S.), Cognizant combines a passion for client satisfaction, technology innovation, deep industry and business process expertise, and a global, collaborative workforce that embodies the future of work. With over 100 development and delivery centers worldwide and approximately 233,000 employees as of March 31, 2016, Cognizant is a member of the NASDAQ-100, the S&P 500, the Forbes Global 2000, and the Fortune 500 and is ranked among the top performing and fastest growing companies in the world. Visit us online at www.cognizant.com or follow us on Twitter: Cognizant.
This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, our expectations regarding opportunities in the marketplace and our anticipated financial performance, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those expressed or implied include general economic conditions and the factors discussed in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Cognizant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.